We highlight the results obtained by our partner Ariela Agosin and partners Eugenio Gormáz and Antonio Rubilar.

The prestigious French publication Leaders League recognized the work of our firm in eight categories this year 2024.

On this occasion, the excellent multidisciplinary work carried out by our IP, Tech and Data and Public Law and Regulated Markets groups was highlighted.

In 2024, we are highlighted as “Leading” in Enforcement & anti-counterfeiting actions, IP litigation, Patent litigation, Patent prosecution, Technology and Trademark prosecution.

In addition to the above, we have obtained the recognition of “Excellent” in Regulatory law for health, pharma, and medical devices. We have also been rated as “Highly recommended” in Plant Varieties Protection.

We are grateful for the commitment and dedication of those who make this notable distinction possible in the following categories:

  • Enforcement and Anti-Counterfeiting Actions | Leading | Ariela Agosin – Eugenio Gormáz
  • IP Litigation | Leading | Ariela Agosin | Eugenio Gormáz
  • Patent litigation | Liderando | Ariela Agosin | Eugenio Gormáz
  • Patent prosecution | Liderando | Ariela Agosin | Eugenio Gormáz
  • Plant Variety Protection | Highly Recommended | Eugenio Gormáz
  • Health, Pharmaceutical and Medical Devices Regulatory Law | Excellent | Antonio Rubilar
  • Technology : Outstanding | Eugenio Gormáz
  • Trademark prosecution | Outstanding | Ariela Agosin – Eugenio Gormáz.

This achievement would not have been possible without the work and dedication of our talented team. We would especially like to congratulate our partner Ariela Agosin and associates Eugenio Gormáz and Antonio Rubilar.

The results are available here.

We share the contact information of our partners and directors recognized in this opportunity:

Ariela Agosin | Partner | aagosin@az.cl

Eugenio Gormáz | Partner | egormaz@az.cl

Antonio Rubilar | Partner | arubilar@az.cl


Be part of our multimedia platform and receive the latest legal news, events, podcazt and webinars.

Subscribe to our Newsletter here.